State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. Blood cancer journal Ryan, C. E., Ahn, I. E., Sekar, A., Rawstron, A., Almeida, J., Martin-Subero, I., Parry, E. M., Alcoceba, M., Calado, D. P., Orfao, A., Langerak, A. W., Veelken, H., Langerbeins, P., Stephens, D. M., Parikh, S. A., Niemann, C. U., Roulland, S., Stamatopoulos, K., Slager, S. L., Shanafelt, T., Ghia, P., Okosun, J., Davids, M. S. 2025; 15 (1): 148

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

View details for DOI 10.1038/s41408-025-01341-6

View details for PubMedID 40883275

View details for PubMedCentralID 8057266